Related Experiment Video
Updated: Jan 24, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways
1Department of Nephrology, the Affiliated Hospital of Nantong University, Nantong, China. chenxl8448@sina.com.
Objective:
The aim of this study was to investigate whether Lixisenatide, NF-kB/TNF-α, and TGF-β/Smad pathways exert clear regulatory roles in doxorubicin-induced renal fibrosis in rats, and to explore the possible underlying mechanism.
Materials And Methods:
30 rats were randomly assigned into the sham group, the Doxorubicin (DOX) group and the Lixisenatide group, 10 in each group. Eight weeks after the specific animal procedure, serum and kidney samples of rats were collected. The serum levels of Cr and BUN were detected using relative commercial kits. The activities of malondialdehyde (MDA), total antioxidant capacity (T-AOC), catalase (CAT), reduced glutathione (GSH), and superoxide dismutase (SOD) in kidney homogenate were accessed using commercial kits. Meanwhile, pathological lesions in kidney tissues were evaluated by HE staining, immune-histochemical staining and TUNEL assay, respectively. Also, the protein levels of relative genes in NF-kB/TNF-α, and TGF-β/Smad pathways in rat kidneys were determined by immune-histochemical staining and Western blot, respectively.
Results:
Rats in the Lixisenatide group showed significantly lower levels of Cr and BUN. Activities of T-AOC, CAT, GSH, and SOD in the Lixisenatide group were significantly higher, whereas MDA activity was significantly lower than in the DOX group. Lixisenatide treatment remarkably alleviated DOX-induced pathological lesions and cell apoptosis in kidneys. Furthermore, the protein levels of relative genes in NF-kB/TNF-α and TGF-β/Smad pathways in rat kidneys were significantly downregulated in the Lixisenatide group when compared with the DOX group.
Conclusions:
Lixisenatide protects doxorubicin-induced renal fibrosis in rats by inhibiting NF-κB/TNF-α and TGF-β/Smad pathways.
Insights
Lixisenatide treatment effectively protected against doxorubicin-induced renal fibrosis in rats by inhibiting key inflammatory pathways, including NF-kB/TNF-α and TGF-β/Smad.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Background:
- Doxorubicin (DOX) is a potent chemotherapy agent with known nephrotoxic effects, often leading to renal fibrosis.
- The precise molecular mechanisms underlying DOX-induced renal fibrosis, particularly the roles of NF-kB/TNF-α and TGF-β/Smad pathways, require further elucidation.
Purpose of the Study:
- To investigate the protective effects of Lixisenatide against doxorubicin-induced renal fibrosis in a rat model.
- To determine whether Lixisenatide modulates the NF-kB/TNF-α and TGF-β/Smad signaling pathways in the context of DOX-induced kidney injury.
Main Methods:
- A rat model of doxorubicin-induced renal fibrosis was established, with animals randomized into sham, DOX, and Lixisenatide treatment groups.
- Kidney function markers (Cr, BUN), oxidative stress indicators (MDA, T-AOC, CAT, GSH, SOD), and renal histopathology were assessed.
- Protein expression levels of key genes within the NF-kB/TNF-α and TGF-β/Smad pathways were quantified using immunohistochemistry and Western blot.
Main Results:
- Lixisenatide treatment significantly improved renal function, evidenced by reduced serum creatinine (Cr) and blood urea nitrogen (BUN) levels.
- Lixisenatide administration attenuated oxidative stress and reduced kidney tissue damage and apoptosis induced by doxorubicin.
- The expression of proteins involved in the NF-kB/TNF-α and TGF-β/Smad pathways was significantly downregulated in the Lixisenatide-treated group compared to the DOX group.
Conclusions:
- Lixisenatide demonstrates significant renoprotective effects against doxorubicin-induced renal fibrosis in rats.
- These protective effects are mediated through the inhibition of the NF-kB/TNF-α and TGF-β/Smad signaling pathways.
- Lixisenatide represents a potential therapeutic agent for mitigating chemotherapy-induced kidney damage.
Related Concept Videos
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Conjugate Addition to α,β-Unsaturated Carbonyl Compounds
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Zones of Protection
Protective zones are defined by closed dashed lines, containing one or more components. A key characteristic of these zones is the strategic placement of...

